checkAd

EQS-News Relief Points to Applied Pharma Research (APR) News re: Pivotal COVID-19 Trial Initiation with Novel Nasal Spray

Nachrichtenquelle: EQS Group AG
17.05.2021, 07:00  |  146   |   |   

EQS Group-News: RELIEF THERAPEUTICS Holdings AG / Key word(s): Study
Relief Points to Applied Pharma Research (APR) News re: Pivotal COVID-19 Trial Initiation with Novel Nasal Spray

17.05.2021 / 07:00


Relief Points to Applied Pharma Research (APR) News re: Pivotal COVID-19 Trial Initiation with Novel Nasal Spray

Geneva, Switzerland, May 17, 2021 - RELIEF THERAPEUTICS Holding AG (SIX: RLF, OTCQB: RLFTF)("Relief"), a biopharmaceutical company with its lead compound RLF-100TM (aviptadil) in advanced clinical development to treat COVID-19-induced lung injury, is pleased to see the recent announcement by APR Applied Pharma Research S.A. ("APR") regarding the initiation of a pivotal clinical trial with its novel nasal spray, temporarily codenamed APR-AOS2020, a Class III medical device, in patients with mild COVID-19. The trial is designed to evaluate the efficacy and safety of the product in reducing viral load in the upper respiratory airways in recently infected individuals. The APR press release can be found here.

"We are very happy to see the start of this pivotal clinical trial with one of the main product candidates in APR's portfolio so shortly after we signed the binding term sheet to acquire all shares of this exciting company," Jack Weinstein, Chief Financial Officer and Treasurer of Relief, said. "We strongly believe that the acquisition of APR will fit perfectly with Relief's strategy to expand our clinical pipeline as it will add synergistic and promising late-stage candidates to treat various indications in rare or debilitating diseases with high unmet medical needs, in addition to marketed products. We are very much looking forward to working with APR and advance our joined product pipeline as quickly as possible to reach patients."

Relief and APR, a privately held Swiss pharmaceutical company with over 25 years' experience in identifying, developing and commercializing known molecules engineered with drug delivery systems in niche and rare diseases on a global basis, announced on May 4, 2021 that the companies had signed a binding term sheet for Relief to acquire all outstanding shares of APR. See "Relief and Applied Pharma Research (APR) Sign Binding Term Sheet for Relief to Acquire All Outstanding Shares of APR." For a period of 60 days, Relief has the exclusive right to negotiate and close the transaction on the basis of the terms and conditions in the signed Term Sheet. With APR's products already on the market, the acquisition will provide Relief with commercial revenues and provide access to an established commercial organization in key European markets that Relief hopes to leverage for other programs. In addition, Relief will gain a robust clinical portfolio in rare or debilitating diseases with high unmet medical need that is synergistic with Relief's current development pipeline.

Seite 1 von 3
RELIEF THERAPEUTICS Holding Aktie jetzt über den Testsieger (Finanztest 11/2020) handeln, ab 0 € auf Smartbroker.de



Schreibe Deinen Kommentar

Bitte melden Sie sich an, um zu kommentieren. Anmelden | Registrieren

 

Disclaimer

EQS-News Relief Points to Applied Pharma Research (APR) News re: Pivotal COVID-19 Trial Initiation with Novel Nasal Spray EQS Group-News: RELIEF THERAPEUTICS Holdings AG / Key word(s): Study Relief Points to Applied Pharma Research (APR) News re: Pivotal COVID-19 Trial Initiation with Novel Nasal Spray 17.05.2021 / 07:00 Relief Points to Applied Pharma Research …

Community

Nachrichten des Autors

Titel
Titel
Titel
Titel

Nachrichten zu den Werten

ZeitTitel
16.06.21
16.06.21
16.06.21
02.06.21
02.06.21
02.06.21
28.05.21
28.05.21
28.05.21
27.05.21